Princeton Portfolio Strategies Group LLC lowered its stake in shares of Eli Lilly And Co (NYSE:LLY) by 32.7% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 12,334 shares of the company’s stock after selling 5,999 shares during the quarter. Princeton Portfolio Strategies Group LLC’s holdings in Eli Lilly And Co were worth $1,052,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in the stock. Van ECK Associates Corp boosted its stake in shares of Eli Lilly And Co by 10.8% during the 1st quarter. Van ECK Associates Corp now owns 587,502 shares of the company’s stock worth $45,455,000 after acquiring an additional 57,487 shares in the last quarter. IFM Investors Pty Ltd boosted its stake in shares of Eli Lilly And Co by 44.1% during the 2nd quarter. IFM Investors Pty Ltd now owns 44,529 shares of the company’s stock worth $3,800,000 after acquiring an additional 13,637 shares in the last quarter. Hedeker Wealth LLC bought a new stake in shares of Eli Lilly And Co during the 2nd quarter worth about $213,000. Greenleaf Trust boosted its stake in shares of Eli Lilly And Co by 37.7% during the 2nd quarter. Greenleaf Trust now owns 9,815 shares of the company’s stock worth $838,000 after acquiring an additional 2,686 shares in the last quarter. Finally, Private Asset Management Inc. bought a new stake in shares of Eli Lilly And Co during the 2nd quarter worth about $1,206,000. Institutional investors and hedge funds own 76.58% of the company’s stock.

Shares of NYSE:LLY opened at $104.36 on Friday. Eli Lilly And Co has a twelve month low of $73.69 and a twelve month high of $104.94. The company has a market cap of $109.82 billion, a P/E ratio of 24.38, a price-to-earnings-growth ratio of 1.70 and a beta of 0.27. The company has a quick ratio of 1.09, a current ratio of 1.40 and a debt-to-equity ratio of 0.79.

Eli Lilly And Co (NYSE:LLY) last announced its earnings results on Tuesday, July 24th. The company reported $1.50 earnings per share for the quarter, beating the consensus estimate of $1.30 by $0.20. Eli Lilly And Co had a positive return on equity of 39.84% and a negative net margin of 0.60%. The firm had revenue of $6.36 billion during the quarter, compared to the consensus estimate of $6.05 billion. During the same quarter in the prior year, the company earned $1.11 EPS. The firm’s revenue for the quarter was up 9.1% compared to the same quarter last year. equities research analysts forecast that Eli Lilly And Co will post 5.47 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, September 10th. Investors of record on Wednesday, August 15th will be paid a dividend of $0.5625 per share. The ex-dividend date is Tuesday, August 14th. This represents a $2.25 annualized dividend and a yield of 2.16%. Eli Lilly And Co’s payout ratio is 52.57%.

Several analysts have recently issued reports on LLY shares. BMO Capital Markets upped their price target on Eli Lilly And Co from $78.00 to $80.00 and gave the stock a “$89.43” rating in a research note on Thursday, July 19th. TheStreet upgraded Eli Lilly And Co from a “c+” rating to a “b” rating in a research note on Friday, June 29th. JPMorgan Chase & Co. set a $100.00 price target on Eli Lilly And Co and gave the stock a “buy” rating in a research note on Monday, June 11th. Barclays set a $98.00 price target on Eli Lilly And Co and gave the stock a “buy” rating in a research note on Tuesday, May 22nd. Finally, Zacks Investment Research upgraded Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $93.00 price target for the company in a research note on Wednesday, May 30th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $100.13.

In other news, Director Jackson P. Tai purchased 2,168 shares of the business’s stock in a transaction on Thursday, July 26th. The stock was purchased at an average price of $95.22 per share, with a total value of $206,436.96. Following the acquisition, the director now directly owns 53,228 shares in the company, valued at approximately $5,068,370.16. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Christi Shaw sold 8,426 shares of the company’s stock in a transaction that occurred on Tuesday, May 29th. The shares were sold at an average price of $82.10, for a total value of $691,774.60. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,735,639 shares of company stock valued at $160,728,361. 0.11% of the stock is owned by corporate insiders.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

See Also: How do investors use RSI to grade stocks?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.